Tratamiento de la paralisis cerebral

Translated title of the contribution: Cerebral paralysis therapy

O. Papazian, I. Alfonso

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Unfortunately, in spite of the advances in foetal and perinatal medicine in the last twenty years, the incidence of cerebral palsy has remained unchanged (1.5-2.5 per 1000 live births). It has even possibly risen slightly in premature babies of low birth weight, in parallel with the increased survival of these babies. In spite of modern techniques of rehabilitation, 25% of these patients cannot walk and 35% are mentally retarded. This costs society 5,000 million dollars annually, not counting the loss of opportunity and the emotional and economic burden imposed on these families. The development of new preventive measures such as the use of antagonists of the cortical excitatory amino acids (which when in excess may cause irreversible cerebral damage in cases of hypoxic-ischaemic encephalopathy of the new born). Intramuscular botulinum toxin and continuous intrethecal baclofen seem to promise a reduction in the incidence and functional incapacity of cerebral palsy.

Translated title of the contributionCerebral paralysis therapy
Original languageSpanish
Pages (from-to)728-739
Number of pages12
JournalRevista de Neurologia
Issue number141
StatePublished - May 1997


  • baclofen
  • botulinum toxin
  • cerebral palsy


Dive into the research topics of 'Cerebral paralysis therapy'. Together they form a unique fingerprint.

Cite this